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Abstract: Ischemia and reperfusion of organs is an unavoidable consequence of transplantation. Inflammatory events  
associated with reperfusion injury are in part attributed to excessive complement activation. Systemic administration  
of complement inhibitors reduces reperfusion injury but leaves patients vulnerable to infection. Here, we report a   
novel therapeutic strategy that decorates cells with an anti-complement peptide. An analog of the C3 convertase inhibitor 
Compstatin (C) was synthesized with a hexahistidine (His6) tag to create C-His6. To decorate cell membranes with C-His6, 
fusogenic lipid vesicles (FLVs) were used to incorporate lipids with nickel (Ni
2+) tethers into cell membranes, and these 
could then couple with C-His6. Ni
2+ tether levels to display C-His6 were modulated by changing FLV formulation, FLV 
incubation time and FLV levels. SKOV-3 cells decorated with C-His6 effectively reduced complement deposition in a 
classical complement activation assay. We conclude that our therapeutic approach appears promising for local ex vivo 
treatment of transplanted organs to reduce complement-mediated reperfusion injury. 
Keywords: Complement, Complement inhibitors, Compstatin, Drug delivery, Liposomes, Ischemia, Reperfusion, Cell membrane.  
INTRODUCTION 
  Since the original description of complement activation 
observed in ischemic hearts [1], there is growing evidence 
that complement is a central mediator of ischemia/reper- 
fusion (IR) injury (IRI) [2-4]. After decades of neglect, com-
plement has been rediscovered as a potent mediator of in-
flammation and rejection in organ transplants. Studies have 
shown that IR-induced complement activation leads to the 
formation of several key inflammatory mediators that alter 
vascular homeostasis and stimulate leukocyte activation and 
chemotaxis [2, 4-6]. Depending on the type of tissue in-
volved, IR-induced complement activation may occur via the 
classical and/or alternative pathways [4, 7]. Under normal 
conditions, the vascular endothelial cells express CD59, 
CD46, CD55 and C receptor 1 (CR1), which offer protection 
against constant low-level complement activation in plasma 
[8]. However, following organ transplantation, the inevitable 
IR activates complement to greater levels than normal,   
rapidly overwhelming natural anti-complement defenses. To 
curtail IR-induced or unwanted complement activation,   
soluble forms of CR1, CD59, CD46 and CD55 have been 
developed [9, 10], but due to their non-specific nature these 
agents inactivate complement systemically thereby placing 
the recipients at increased risk of iatrogenic disease. 
  At present, second generation agents aimed at targeting 
specific cells or tissues are being developed for clinical use  
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[11-15]. However, the success rate has been disappointingly 
low. Some of these targeted agents continue to have draw-
backs, including: 1) Systemic delivery with generalized 
complement suppression; 2) Dosing issues due to depend-
ence on expression levels of targeted membrane proteins, 
which varies between individuals and/or in the presence of 
pathological conditions; and 3) Cost effectiveness of recom-
binant protein products requiring multiple manufacturing 
steps, which may prove prohibitive for clinical use [11]. To 
address these issues, we developed a novel and relatively 
inexpensive therapeutic approach for the local delivery of 
synthetic anti-complement peptides to be used in transplanta-
tion or in by-pass procedures. Our approach takes advantage 
of an inherent property of small unilamellar fusogenic lipid 
vesicles (FLVs) [16], which when fusing with cells incorpo-
rate their lipids into cell membranes. FLVs are formulated 
with a mixture of three lipids, one of them containing a 
nickel (Ni
2+) tether. After FLVs fuse with cells, Ni
2+ tethers 
are displayed on the membrane surface and can be used as 
linkers to decorate cells with a bi-functional peptide com-
prised of a hexahistidine (His6) Ni
2+-tether-binding domain 
and an anti-complement domain. Liposomes formulated with 
lipids containing functional groups to bind proteins or anti-
bodies for either targeting or to increase fusogenicity have 
been previously reported (reviewed in reference [17]). 
Liposomes formulated with a metal chelating lipid have been 
incubated with tumor cells with the purpose of displaying 
recombinant co-stimulatory proteins for potential use as anti-
cancer vaccines [18]. To our knowledge, the use of FLVs to 
display anti-complement peptides on the surface of cell 
membranes to control complement activation has not been 
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  The purpose of this study was to determine whether a 
therapeutic strategy based on the decoration of cells with a 
small bi-functional anti-complement peptide would be effec-
tive in reducing complement deposition in vitro. Compstatin 
(C), a small peptide known to inhibit classical or alternative 
C3 convertase by preventing C3 cleavage [19-22], was se-
lected to create a bi-functional analog by adding a His6-tag to 
C and produce C-His6. Here, we report that cells treated with 
FLVs containing Ni
2+ tethers and incubated with C-His6, 
displayed the bi-functional peptide on cell membranes and 
effectively reduced complement deposition in a classical 
activation assay. 
MATERIALS AND METHODS 
C-His6 Synthesis 
  The original C peptide sequence Ile1-[Cys2-Val3-Val4-
Gln5-Asp6-Trp7-Gly8-His9-His10-Arg11-Cys12]-Thr13-NH2 
was modified as previously described to increase potency 
with substitutions: Val4 to 2-naphthylalanine (2Nal) and 
His9 to Ala [23]. Furthermore, a His6-tag was added to the 
C-terminus of the peptide. Solid phase peptide synthesis us-
ing Fmoc strategy on a Rink amide resin was used to synthe-
size C-His6. The peptide was purified using HPLC. 
C-His6 Bioactivity Assay 
  Antibody-sensitized sheep erythrocytes (Sigma-Aldrich, 
St. Louis, MO) were used to perform a hemolytic comple-
ment assay to test C-His6 inhibition. The cells were washed 
and re-suspended in Gelatin Veronal Buffer (GVB) (Sigma-
Aldrich, St. Louis, MO) at a concentration of 1x10
8 cells/mL 
and then aliquoted in a 96 well microtiter plate at 100μL/ 
well. C-His6 was serially diluted in 1:20 human serum/GVB 
from 0.015M to 0.0039M in 2:3 parts/volume ratio. 
100μL of this solution was then added to the cells and incu-
bated with constant shaking for an hour at 37
°C. 150μL of 
ice-cold GVB was added to all the wells to inhibit further 
complement activity. The plate was then centrifuged at 800G 
for 10 min at 4
°C. After removing the supernatants, they 
were transferred to a 96 well microtiter plate and absorbance 
readings were obtained at 414nm. The 100% lysis value was 
obtained by suspending cells in water and the minimal value 
was obtained by suspending cells in GVB only. 
Cell Culture 
  Human skin fibroblasts were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma Inc. St Louis, 
MO) supplemented with: 10% Fetal Bovine Serum (FBS), 
2mM L-Glutamine and 100U/mL of Penicillin/Streptomycin 
mixture. Ovarian carcinoma (SKOV-3) cells were incubated 
in McCoy’s Complete Medium (Caisson Labs, North Logan, 
UT) with 10% FBS, 2mM L-Glutamine and 100U/mL of 
Penicillin/Streptomycin. Both cell types were then seeded in 
75cm
2 flasks and maintained in a tissue culture incubator at 
37
°C with 5% CO2 and 90% humidity.  
Fusogenic Lipid Vesicle Synthesis 
  FLVs were formulated with various molar ratios of 1,2-
Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC), 1-Palmitoyl- 
2-Oleoyl-sn-Glycero-3-Phosphate (Monosodium Salt) (POPA) 
and 1,2-Dioleoyl-sn-glycero-3-{[N(5-amino-1-carboxypentyl)  
iminodiacetic acid] Succinyl} (Nickel Salt) (DOGS-NTA-
Ni
2+) (Avanti Polar Lipids, Alabaster, AL). The molar ratios 
of DOPC, POPA, and DOGS-NTA-Ni
2+ were varied to op-
timize Ni
2+ tether incorporation onto cell membranes. Lipids 
in liquid chloroform were mixed in a glass flask, and the 
mixture was dried under nitrogen gas. The mixture was fur-
ther desiccated overnight in a vacuum chamber. The lipids 
were rehydrated in Ca
2+/Mg
2+-free PBS buffer at a concen-
tration of 1mg/mL, vortexed for 1 min and incubated in a 
37
°C bath for 5 min. This cycle was repeated 6 times, and the 
resulting solutions of multi-lamellar lipid vesicles were soni-
cated with a Branson Sonifier® 450A (Branson Ultrasonics 
Corp, Danbury, CT) at 50% duty cycle for 1 min/mL to form 
smaller unilamellar FLVs. 
Functionalization of Cell Membranes with Ni
2+ Tethers  
  These experiments were performed using fibroblasts and 
SKOV-3 cells. FLV formulations were optimized using fi-
broblasts because of their hardiness and excellent ability to 
remain attached to well bottoms. Subsequent experiments 
were conducted on SKOV-3 cells to characterize the effects 
of FLV levels and incubation time prior to performance of 
complement deposition studies on these cells. FLV formula-
tions were optimized by varying the molar ratio of DOGS-
NTA-Ni
2+ thus changing the final levels of Ni
2+chelated lipid 
from 40 to 87ng/L. Fibroblasts were first seeded in a 96 
well microplate coated with 0.5% porcine gelatin solution 
(Sigma-Aldrich, St. Louis, MO) at a density of 8 x 10
4 
cells/well and incubated for 12 hr at 37
°C with 5% CO2 and 
90% humidity. Cells were then washed twice with PBS and 
treated for 20 min with FLVs formulated with the following 
DOGS-NTA-Ni
2+ concentrations: 40, 52, 64, 75 and 87 
ng/L. Eight wells per lipid concentration were tested.   
To assess Ni
2+ tether incorporation, cells were incubated for  
30 min with 0.2ng/L of truncated His6-Cardiotrophin 
(BioVendor Laboratory Medicine, Inc. Brno, Czech Repub-
lic) and with 0.01 μg/μL of FITC- labeled anti-His6 antibody 
(Alpha Diagnostic, San Antonio, TX) for 15 min. (His6-
Cardiotrophin was used as a probe to demonstrate that other 
His6-tagged agents would couple to lipid-tethered Ni
2+ and 
that the FITC- labeled anti-His6 antibody was an effective 
method to quantify Ni
2+ tethers on membranes). All the wells 
were washed thrice with PBS between incubation treatments. 
Background controls did not receive FLVs but were incu-
bated with His6-Cardiotrophin and FITC- labeled anti-His6 
antibody. Antibody-specific fluorescence was measured us-
ing a SpectraMax M2
 (Molecular Devices, Sunnyvale, CA) 
microplate reader at 494nm excitation and 518nm emission. 
Reported values were corrected for background. 
  Similar experiments were performed with SKOV-3 ovar-
ian carcinoma cells to determine the effect of FLV concen-
tration on tether incorporation and C-His6 binding. Cells 
were seeded at a density of 8 x 10
4 cells/well in 96 well mi-
croplates and exposed for 20 min to FLVs formulated with 
64ng/L DOGS-NTA-Ni
2+ diluted in PBS to achieve final 
lipid concentrations ranging from 12.5 to 500μg/mL. Cells 
were incubated with 0.01μg/μL of C-His6 for 30 min and 
with FITC- labeled anti-His6 antibody for 15 min. All wells 
were washed thrice between steps, and fluorescence was 
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  The relation between FLV incubation time and incorpo-
ration of Ni
2+ tethers was characterized by incubating 
SKOV-3 cells for 10 to 50 min with FLVs (500g/mL) for-
mulated with DOGS-NTA-Ni
2+ (64ng/L). Cells were incu-
bated with 0.01μg/μL of C-His6 for 30 min and with FITC- 
labeled anti-His6 antibody for 15 min. All wells were washed 
thrice between steps, and fluorescence was measured as   
described above. 
Quantification of C-His6 Levels on Cell Membranes  
  To quantify C-His6 levels displayed on cell membranes 
following FLV/C-His6 treatment, a direct analysis assay us-
ing UV absorbance was performed on a SpectraMax M2 
(Molecular Devices) microplate reader. The assay was based 
on detecting the 2Nal residue of the C-His6 sequence, which 
we estimated to have a peak absorbance in the 280-290nm 
range. To determine the optimal wavelength for C-His6 ab-
sorbance, various concentrations of the peptide were serially 
diluted in half starting at 0.2g/L and ending at 0.00625g/ 
L. Three 100 L aliquots per dilution were placed on a   
96-well plate. The UV absorbance was measured repeatedly 
at 2nm increments starting at 270nm until a maximum dif-
ference between dilutions was observed, measurements con-
tinued at higher wavelengths until differences between sam-
ples were no longer apparent at 300nm.  
  To quantify membrane-bound C-His6 levels, SKOV-3 
cells were seeded in Costar 12 well plates and allowed to 
reach confluence. Cells were incubated for 50 min with 
FLVs (500g/mL) and without FLVs. All cells were washed 
thrice and incubated with 1mL of 0.10 g/L of C-His6 for 
30 min. Cells were washed thrice, and to release membrane-
bound C-His6, cells were incubated with 330L of PBS (pH 
4) for 10 min. 100L from each well were drawn, placed in a 
96 well microplate and UV absorbance was measured at 284 
nm. The mean absorbance values were converted to C-His6 
levels using a standard curve of known concentrations and 
adjusted to levels per mL. C-His6 levels per membrane area 
were calculated using the well’s bottom surface area 
(38.3mm
2) under the assumption that this area was equiva-
lent to the cells’ non-adherent membrane area at 100% con-
fluence. 
Time Course Experiments 
  To determine the duration of C-His6 display on cell 
membranes, fibroblasts were seeded in Costar 12 well plates 
and allowed to reach ~90% confluence. Cells were incubated 
for 30 min with FLVs (500g/mL) and without FLVs. All 
cells were washed twice and incubated with 1mL of 0.1 
mg/mL of C-His6 for 30 min. Cells were washed and incu-
bated in cell media. Levels of C-His6 were quantified after 
treatment, at 24 and 48 hours. The same methods used to 
quantify C-His6 levels displayed on cell membranes in the C-
His6 quantification section above were used in these experi-
ments. Membrane-bound C-His6 was released by incubating 
cells in 330L of PBS (pH 4) for 10 min. Three 100L ali-
quots from each well were drawn, placed in separate wells in 
a 96 well microplate, and UV absorbance was measured at 
284 nm. Absorbance values were converted to C-His6 levels 
in solution using a standard curve, and levels of peptide at 
the various time points were compared. The experiment was 
repeated five times and the results were averaged. 
Complement C3b Deposition Assay 
  We used the protocol described by B.P. Morgan with 
some modifications to quantify the inhibitory effect of C-
His6 [24]. SKOV-3 cells were seeded in 96 well microtiter 
plates and allowed to reach 90% confluence. Cell mem-
branes were functionalized with Ni
2+ tethers by incubating 
for 40 min with FLVs containing 64ng/μL of DOGS-NTA-
Ni
2+. Cells were subsequently incubated for 30 min with 
various concentrations of C-His6 (0.05-0.2 μg/μL). Control 
cells did not receive any treatment. Cells were then lifted off 
the plate with Cellstripper
TM (Mediatech Inc Herndon, VA), 
washed in 3% BSA/PBS and re-suspended at 1x10
6 cells/mL 
in flow cytometry tubes. Trastuzumab (Herceptin) was then 
added at 0.05μg/μL and the cells were kept at 4°C for 30 
min. Each tube was washed with 2mL of McCoy’s medium, 
centrifuged at 300G for 10 min and re-suspended in 1:2 dilu-
tion of fresh human serum. The samples were subsequently 
incubated at 37°C, 5% CO2, 90% humidity for 30 min with 
intermittent agitation, washed again in minimal media 
(M119, 1%FBS) and re-suspended in 1:100 dilution FITC-
conjugated goat anti-human F(ab’)2 fragment antibody to C3 
(MP-Biomedicals, Solomon, OH). The cells were kept at 
4°C for 30 min then centrifuged for 5 min at 300G at 4°C, 
and re-suspended in 500μL of minimal media. 10μL of 
propidium iodide (PI) was added to identify dead cells. All 
cells were washed with PBS between treatment steps. Con-
trol groups without C-His6 were included to assess spontane-
ous complement deposition, non-specific antibody binding, 
and maximal complement deposition. PI-positive cells were 
excluded from the analyzed sample and fluorescence emitted 
by live cells in the FITC channel was quantified for control 
and experimental groups using the FlowJo software program 
(Tree Star, Inc., Ashland, OR). 
Statistical Analysis 
  Data from formulation, concentration and incubation 
time experiments were analyzed for statistical significance 
by a one-way ANOVA followed by post-hoc pairwise com-
parisons. Differences between control groups and experi-
mental groups were evaluated using Tukey’s test. In experi-
ments in which two groups were being compared, a student’s 
t-test was performed. The differences between treatment and 
control groups as measured by flow cytometry was deter-
mined with a chi-square univariate analysis (FlowJo, version 
8.8.6) [25]. A P value of <0.05 was considered significant. 
Data is reported as means ± SEM. 
RESULTS 
Bioactivity of C-His6 
 Once  C-His6 was synthesized and purified to >95%   
purity, the peptide was tested for bioactivity using a   
hemolytic complement assay. The normalized dose response 
relationship between C-His6 concentration and hemolytic 
inhibition are shown in Fig. (1). The EC50 was 9.37nM indi-
cating that modification with a His6 tag did not render C-His6 
inactive. 160    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Goga et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). C-His6 inhibition curve of complement mediated erythro-
cyte lysis. Antibody sensitized sheep erythrocytes were suspended 
in 1:20 human serum/gelatin veronal buffer (GVB) and treated with 
serial dilutions of C-His6. The 100% lysis value was obtained by 
suspending cells in water and the minimal value was obtained by 
suspending cells in GVB only. The normalized data gave an EC50 
value of 9.37nM indicating that the peptide remained bioactive after 
incorporating the His6-tag. 
Optimization of FLV Formulation to Maximize Ni
2+ 
Tether Display  
  To determine composition of FLV formulations that 
would optimally incorporate Ni
+ tethers in membranes, a 
series of experiments altering levels of DOGS-NTA-Ni
2+ 
were performed. In previous studies (data not shown) which 
characterized the fusogenicity of FLVs formulated with 
DOPC-POPA mixtures, we had established that POPA levels 
are critical to the fusogenic properties of FLVs. In this study, 
we kept the levels of POPA constant while varying the levels 
of DOPC and DOGS-NTA-Ni
2+. Fig. (2) shows that, as the 
levels of DOGS-NTA-Ni
2+ were increased, Ni
2+ tether incor-
poration appeared to peak significantly at concentrations 
between 64 and 75ng/L.  
Functionalization of Cell Membranes with Ni
2+ Tethers  
  To further characterize the efficiency of FLVs in incor-
porating Ni
2+ tethers in cell membranes, incubation time and 
dose response studies were performed. FLVs formulated 
with DOPC : POPA : DOGS-NTA-Ni
2+ at molar percentages 
of 20:57:23 successfully incorporated Ni
2+ tethers on SKOV-
3 cell membranes in a time-dependent manner (Fig. 3) and 
dose-dependent manner (Fig. 4). These results suggest that 
Ni
2+ tether incorporation in membranes can be modulated 
and carefully controlled by altering FLV incubation time, 
FLV concentration or both.  
Quantification of C-His6 Levels on Cell Membranes  
  To directly quantify anti-complement peptide levels cou-
pled to Ni
2+ tethers on the membrane surface, we performed 
preliminary studies using UV absorbance, and determined 
that a wavelength of 284nm was optimal to discern C-His6 
levels diluted in PBS. Following FLVs/C-His6 (0.1g/L) 
treatment, the mean levels of three experiments showed   
that membrane-bound C-His6 was significantly higher   
(94.4  ± 8.4g) than in cells treated with C-His6 alone   
(18.6 ± 7.9g, P=0.0026). These results indicate that C-His6 
was not only binding to Ni
+ tethers incorporated in mem-
branes but also binding non-specifically. Fig. (5) shows the 
calculated levels of C-His6 displayed per surface area of 
membrane.  
Time Course Experiments 
  To determine whether membrane-localized anti-
complement peptide would be displayed by cells for 48 h, 
fibroblasts were treated with FLVs/C-His6 therapy, and lev-
els of C-His6 were quantified at 0 h, 24 h and 48 h post-
treatment. As shown in Fig. (6), C-His6 display was stable 
 
 
 
 
 
 
 
 
 
Fig. (2). Varying levels of DOGS-NTA-Ni
2+ in FLV formulations altered Ni
2+ tether incorporation in fibroblast cell membranes. Cells were 
incubated (20 min) with FLVs formulated with various molar ratios of DOPC : POPA : DOGS-NTA-Ni
2+ (n=8 wells per formulation). Cells 
were washed and incubated (30min) with a truncated His6-tagged protein (Cardiotrophin-His6), an additional wash was performed, and cells 
were incubated (15 min) with FITC-labeled anti-His6 antibodies. FLVs formulated with 64 and 75ng/L of DOGS-NTA-Ni
2+ bound greater 
amounts of Cardiotrophin-His6, indicating greater incorporation of Ni
2+ tethers. Bars represent mean fluorescence levels ± SEM. * indicates 
P< 0.05 compared to #. A Novel Anti-complement Therapy  The Open Cardiovascular Medicine Journal, 2010, Volume 4    161 
over 48 h. There was no statistical significance between 
mean C-His6 levels released by the low pH buffer at the three 
time points. However, in all experiments there was a trend 
for higher C-His6 levels released at 24 h.  
 
 
 
 
 
 
 
Fig. (3). FLV incubation incorporated Ni
2+ tethers in cell membranes in a time-dependent manner. SKOV-3 cells were incubated with FLVs 
for various time periods (n=8 wells per time period). Cells were washed and incubated (30 min) with C-His6, an additional wash was per-
formed, and cells were incubated (15 min) with FITC-labeled anti-His6 antibodies. Bars represent mean fluorescence levels ± SEM. 
 
 
 
 
 
 
 
 
Fig. (4). Increasing FLV levels increased Ni
2+ tether incorporation in SKOV-3 cell membranes in a dose-dependent manner. Cells were incu-
bated (20 min) with various concentrations of FLVs (n=8 wells per lipid concentration). Cells were washed and incubated (30 min) with C-
His6, an additional wash was performed, and cells were incubated (15 min) with FITC-labeled anti-His6 antibodies. Bars represent mean 
fluorescence levels ± SEM. 
 
 
 
 
 
 
 
Fig. (5). Levels of Ni
2+-tether-bound C-His6 per area of cell membrane is shown. Cells (100% confluence) in 12-well plates were incubated 
(50 min) with and without FLVs. Cells were washed and incubated (30 min) with 1mL of 0.10 mg/mL of C-His6. Cells were washed, and 
membrane-bound C-His6 was released by incubating cells for 10 min with 330L of PBS (pH 4). To quantify C-His6, three 100L aliquots 
from each well were drawn, placed in separate wells of a 96-well plate and UV absorbance was measured at 284 nm. C-His6 levels per sur-
face area were calculated using a C-His6 standard curve and the surface area of the well’s bottom (38.3mm
2). * indicates P< 0.05 when com-
pared to cells without FLV treatment. 162    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Goga et al. 
Complement C3b Deposition Assay 
  To determine whether decoration of anti-complement 
peptide on cell surfaces would decrease complement activa-
tion efficiency, we used HER2/neu-overexpressing human 
ovarian carcinoma SKOV-3 cells. As shown in Fig. (7), anti-
HER2/neu antibody could bind to HER2/neu and potently 
activate complement leading to iC3b deposition (red line). 
The mean fluorescence intensity (MFI) as measured by flow 
cytometry of live SKOV-3 cells with anti-HER2/neu anti-
body plus fresh human serum as a source of complement was 
189 ± 171. In contrast, MFI from SKOV-3 cells treated with 
FLVs and C-His6 was significantly lower than that of un-
treated control cells, reflecting reduced iC3b deposition. 
Cells treated with the highest C-His6 concentration, 
0.2mg/mL (orange line) had a MFI value of 79.1 ± 43.9 as 
compared to untreated control (red line) which had a MFI 
value of 189 ± 171 with P<0.01 for both groups (0.05mg/mL 
and 0.2 mg/mL). These data suggest that indeed localization 
of anti-complement peptide to cell surfaces significantly 
impairs potent complement activation.  
DISCUSSION 
  We present a novel approach of incorporating small pep-
tides onto the surface of cell membranes; an approach that 
has potential application in the development of anti-
complement therapies. The purpose of this study was two-
fold. First, we wished to demonstrate that FLVs formulated 
with a novel combination of lipids can efficiently allow the 
display of a small anti-complement peptide on cell mem-
branes for at least 48 h. Second, we wanted to provide proof-
 
 
 
 
 
 
Fig. (6). Time course of C-His6 displayed on fibroblast membranes following FLV/C-His6 treatment. Cells in 12-well plates were allowed to 
reach ~90% confluence. Cells were incubated (30 min) with and without FLVs. Cells were washed and incubated (30 min) with 1mL of 0.1 
mg/mL of C-His6. Cells were washed and incubated at 37°C in cell media for 0, 24 and 48 h. At the end of each time point, cells were 
washed, and membrane-bound C-His6 was released by incubating cells (10 min) with 330L of PBS (pH 4). To quantify C-His6, three 100L 
aliquots from each well were drawn, placed in separate wells of a 96-well plate and UV absorbance was measured at 284 nm. C-His6 levels 
were calculated using a C-His6 standard curve. Five experiments were combined and there was no statistical significance between the three 
time points. 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Flow cytometry analysis demonstrated that decoration of SKOV-3 cells with C-His6 reduced complement deposition (C3b) in a 
classical activation assay. All cell groups except for the untreated controls (dark blue) were incubated with trastuzumab and FITC-labeled 
anti-C3b antibodies. One group was incubated without serum (green) to determine non-specific C3b antibody binding. One group served as 
the positive control (red) and two groups were treated with FLVs and C-His6 at two different concentrations: 0.05 mg/mL (light blue) and 
0.2mg/mL (orange). FLVs/C-His6 (0.2mg/mL and 0.05mg/mL) treatment reduced C3b deposition significantly compared to untreated posi-
tive controls with P< 0.01. A Novel Anti-complement Therapy  The Open Cardiovascular Medicine Journal, 2010, Volume 4    163 
of-concept that the membrane-immobilized peptide is able to 
reduce complement deposition in a classical activation assay. 
Our data provides evidence that the lipids used in our FLV 
formulation produced vesicles that rapidly fused with cells 
without the aid of fusogens, and after FLV treatment, cell 
membranes were functionalized with C-His6, protecting cells 
from complement activation. 
  In the literature, various approaches have been reported 
to modify cell membranes with proteins in vitro [26-29]. In 
some approaches, proteins were derivatized to permit their 
direct anchorage to cell membranes by adding lipophilic 
moieties to proteins such as: glycosyl phosphatidylinositol 
[26], palmitic acid [28], and hydrophobic tails [27]. Another 
approach involved the biotinylation of endogenous mem-
brane proteins with sulfo-NHS-LC-biotin to anchor strep-
tavidin-containing chimeric proteins [29]. Although all ap-
proaches were effective in decorating cells, there were dif-
ferences in the time course of display. However, short-term 
or long-term protein display needs to be considered in the 
context of the therapeutic agent’s activity requirements. 
  Liposomes have not been used extensively to modify cell 
membranes although this potential clearly exists. Liposomes 
can be shaped and formulated to work either as long-acting 
sustained release vesicles (low fusogenicity) for drug deliv-
ery or as fusogenic vesicles for intracellular delivery of vari-
ous agents [16, 17, 30-37]. When fusogenic vesicles merge 
with cells, their lipids incorporate into plasma membranes 
and provide an opportunity to modify the cell surface. Two 
research teams have reported modification of cell mem-
branes using fusogenic vesicles. Fadok et al. performed an in 
vitro study in which T cells treated with fusogenic liposomes 
formulated with phosphatidylserine induced co-cultured 
macrophages to engulf what appeared to be apoptotic T cells 
[38]. van Broekhoven et al., in the process of developing a 
cancer vaccine, formulated liposomes with -palmitoyl--
oleoyl-phosphatidylcholine (POPC) and a zinc-chelating 
lipid, nitrilotriacetic acid di-tetradecylamine (NTA-DTDA), 
to display His6-tagged recombinant co-stimulatory molecules 
on murine P815 tumor cells [18]. Using this technique, mice 
immunized with P815 tumor cells bearing B7.1 and CD40 
demonstrated an increased cytolytic T-lymphocyte activity 
against P815 cells and inhibited tumor growth. However, 
their approach had some shortcomings. The vesicle’s lipid 
formulation and construction was not optimal for promoting 
fusion with cells and required the aid of a fusogen (i.e., poly-
ethylene glycol). The time course of protein display was 
relatively short, protein levels (measured using fluorescence 
intensity) decreased rapidly from ~400-fold (immediately 
after treatment) to ~60-fold and ~15-fold by 4 and 24 h, re-
spectively. The authors attributed the loss of displayed pro-
tein to a predominant internalization of the NTA-DTDA-
protein complex by the cell [18]. In the present study, the 
levels of C-His6 displayed on the membrane surface did not 
change significantly over 48 h. These results are very differ-
ent from those obtained by van Broekhoven et al., and we 
attribute the longer duration of peptide display in our study 
to important differences in lipid vesicle formulation, which 
promote vesicle-to-cell fusion without the use of fusogens 
like polyethylene glycol (see comments below). Once fusion 
occurred and vesicle lipids incorporated in the cell mem-
brane, we did not observe changes that would suggest inter-
nalization of the DOGS-NTA-Ni
2+-peptide complex. We 
observed the opposite, at 24 h there was a trend of increasing 
C-His6  levels being released from DOGS-NTA-Ni
2+. This 
non-significant trend (P=0.0825) may represent release of 
either non-specific bound C-His6 or internalized peptide, 
which interacted and coupled with empty Ni
+ tethers over the 
first 24 h period, and later released by the low pH PBS incu-
bation, producing the apparent trend.  
  The construction and formulation of FLVs used in the 
present study differed from those presented by van Broekho-
ven et al. [18]. Our FLV formulation consisted of DOPC, 
POPA and DOGS-NTA-Ni
2+, which was different from their 
formulation (POPC and NTA-DTDA). To increase FLV in-
stability and enhance fusion with cells, we added an asym-
metric lipid (POPA) to disrupt homogeneity of the lipid bi-
layer. Furthermore, our FLVs were created with a high-
frequency sonicator, to produce vesicle populations with a 
tight radius of curvature (~125nm), which increases instabil-
ity of FLV membranes and enhances fusion with cells. Our 
approach did not require any fusogens to boost incorporation 
of DOGS-NTA-Ni
2+ into the cell membrane. Another impor-
tant difference between the two approaches is that Ni
2+ was 
chelated to the lipid before FLV construction eliminating the 
need to add ionized divalent metal to the incubation buffer (a 
potential source for toxicity) during vesicle-cell fusion. Fi-
nally, the therapeutic goal of our approach was not vaccine 
development, but rather to reduce IRI by reinforcing en-
dogenous complement control proteins expressed on cell 
membranes with an anti-complement peptide.  
  The ability to locally deliver complement inhibitors in an 
efficient manner to sites of inflammation can have tremen-
dous benefits in complement-mediated pathology. One obvi-
ous application is in tissue transplantation, which by defini-
tion has to undergo IR. In most tissues prolonged IR is 
known to cause endothelial cell dysfunction due to abnormal 
increases in the reactive oxygen species, increased expres-
sion of adhesion molecules and complement activation [1, 
39-43]. All these factors can contribute toward the functional 
impairment of the endothelial barrier, thereby leading to pro-
tein extravasation and interstitial edema. Several studies 
have also shown that complement activation induced by IR 
leads to the formation of key inflammatory mediators (C3a, 
C5a, C3b and C5b-9) that alter vascular homeostasis and 
stimulate leukocyte activation and chemotaxis [44]. Follow-
ing transplantation pathological changes observed in the 
grafts have been linked to increased complement activation. 
Normally endothelial cells express complement regulatory 
proteins to self-protect from continuous low-level comple-
ment activity in plasma [8]. However, in transplanted grafts 
following IR, these defenses are rapidly overwhelmed and 
endothelial cell damage and dysfunction ensues. Our thera-
peutic approach can enhance endogenous complement con-
trol proteins and reduce tissue injury following IR.  
  Although sCR1 and anti-C5 monoclonal antibody have 
been successful in offering protection against IRI [45, 46], 
long-term systemic inhibition of complement can lead to 
infections and auto-immune diseases [47, 48]. Alternative 
targeted approaches are being developed, including mem-
brane targeting strategies [8, 9, 13]. sCR1sLex (TP20) con-
sisting of soluble CR1 decorated with fucosylated tetrasac-
charide sialyl Lewisx, targets sLex binding sites on E-
selectin and P-selectin adhesion molecules expressed on the 164    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Goga et al. 
endothelium after IR. sCR1-3-MSWP1 (APT070), CD59-
MSWP1 and DAF-MSWP1 consist of fragments of natural 
complement control proteins coupled to the membrane tar-
geting peptide 1 (MSWP1). In animal models of transplanta-
tion and IR injury, TP20 and APT070 have been shown to be 
effective [11, 14, 49, 50]. Although cell membrane-targeted 
agents appear to be promising in IRI animal studies, none 
have been approved for this indication by the FDA [15].  
CONCLUSION 
  In summary, in this study we selected and modified an 
anti-complement peptide to work with our FLV delivery 
system. FLVs allowed control of displayed peptide levels by 
varying formulation, incubation time, and/or concentration 
of FLVs. The peptide remained anchored to the site of com-
plement activation for at least 2 days. Based on the results, 
we conclude that our FLV approach to deliver small peptides 
has potential for local treatment of tissues to reduce IR-
induced complement activation. Our approach appears to be 
well suited for ex vivo treatment of organs in transplantation. 
However, to assess efficacy in vivo, future studies will need 
to be performed in primates since C only inhibits primate-
derived complement.  
ABBREVIATIONS  
ANOVA  =  Analysis of variance 
C =  Compstatin 
DMEM  =  Dulbecco’s Modified Eagle’s Medium 
DOGS-NTA-Ni
2+ = 2-Dioleoyl-sn-Glycero-3-{[N(5-
Amino-1-
Carboxypentyl)iminodiacetic 
acid]succinyl} (nickel salt) 
DOPC =  1,2-Dioleoyl-sn-Glycero-3-
Phosphocholine 
FBS  =  Fetal bovine serum 
FDA  =  US Food and Drug Administration 
FITC =  Fluorescein  isothiocyanate 
FLVs  =  Fusogenic lipid vesicles 
GVB  =  Gelatin veronal buffer 
His6 =  Hexahistidine 
HPLC  = High Performance Liquid Chroma- 
tography 
IR =  Ischemia/reperfusion 
IRI =  Ischemia/reperfusion  injury 
MFI =  Mean  fluorescence  intensity 
MSWP  1  =  Myristoylated electrostatic switch 
peptide 1 
Ni
2+ =  Nickel 
2Nal =  2-naphthylalanine 
NTA-DTDA  =  Nitrilotriacetic acid di-tetradecyl- 
amine 
PBS  =  Phosphate buffered saline 
POPA =  1-Palmitoyl-2-Oleoyl-sn-Glycero-3-
Phosphate(monosodium salt) 
sCR1  =  Soluble complement receptor1 
SEM  =  Standard error of mean 
SKOV-3 =  Ovarian  carcinoma  cells 
UV =  Ultraviolet 
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